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400Background: Secukinumab, a fully human anti-interleukin-17A monoclonal antibody, has shown superior
efficacy to etanercept with similar safety in moderate to severe plaque psoriasis (FIXTURE study).Objective: We sought to directly compare efficacy and safety of secukinumab versus ustekinumab.Methods: In this 52-week, double-blind study (NCT02074982), 676 subjects were randomized 1:1 to
subcutaneous injection of secukinumab 300 mg or ustekinumab per label. Primary end point was 90% or
more improvement from baseline Psoriasis Area and Severity Index (PASI) score (PASI 90) at week 16.Results: Secukinumab (79.0%) was superior to ustekinumab (57.6%) as assessed by PASI 90 response at
week 16 (P\ .0001). The 100% improvement from baseline PASI score at week 16 was also significantly
greater with secukinumab (44.3%) than ustekinumab (28.4%) (P\ .0001). The 75% or more improvement
from baseline PASI score at week 4 was superior for secukinumab (50.0%) versus ustekinumab (20.6%)
(P \ .0001). Percentage of subjects with the Dermatology Life Quality Index score 0/1 (week 16) was
significantly higher with secukinumab (71.9%) than ustekinumab (57.4%) (P\ .0001). The safety profile of
secukinumab was comparable with ustekinumab and consistent with pivotal phase III secukinumab
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Thac¸i et al 401Limitations: The study was not placebo-controlled and of short-term duration.Conclusions: Secukinumab is superior to ustekinumab in clearing skin of subjects with moderate to
severe psoriasis and improving health-related quality of life with a comparable safety profile over 16
weeks. ( J Am Acad Dermatol 2015;73:400-9.)
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d Secukinumab previously demonstrated
superior efficacy to etanercept in
psoriasis, with similar safety.
d CLEAR study demonstrates secukinumab
is superior to ustekinumab in clearing
skin of subjects with moderate to severe
plaque psoriasis and improving quality
of life with comparable safety.
d These head-to-head results are important
to inform treatmentdecisions for psoriasis.Targeted biologic thera-
piesesuch as tumor necrosis
factor (TNF)-a inhibitors
infliximab, etanercept, and
adalimumab and the inter-
leukin (IL)-12/IL-23 anta-
gonist ustekinumabehave
greatly improved the treat-
ment of moderate to severe
plaque psoriasis. In ran-
domized controlled trials,
approximately 50% to 80%
of subjects receiving these bi-
ologics achieved 75%ormore
improvement from baseline
Psoriasis Area and Severity
Index (PASI) score (PASI 75) after 10 to 16 weeks of
treatment.1-8 A 90% improvement from baseline PASI
score, however, is now defined as the threshold of
treatment success per the European Medicines
Agency9 and a ‘‘measure of optimal response’’ by
the American Academy of Dermatology.10 Of note,
90% or more improvement from baseline PASI score
(PASI 90) response was only achieved by
approximately 20% of patients treated with
etanercept,1,2 and approximately 40% to 50% with
infliximab,3,4 adalimumab,5,6 and ustekinumab.7,8
Achieving PASI 90 response in patients with psori-
asis is highly clinically relevant, given the direct
relationship between PASI score improvement and
health-related quality of life (HRQoL).11-13 In 1 study,
44.3% of subjects achieving PASI 90 to less than 100%
improvement from baseline PASI score response and
65.1% achieving 100% improvement from baseline
PASI score (PASI 100) response atweek16 reported no
impact of their skinproblemsonHRQoL, versus 24.3%
of those with PASI 75 to less than PASI 90 response.11
These results support the importance of achieving
PASI 90 toPASI 100 responses inpatientswithpsoriasis
for the maximal improvement in HRQoL.
Secukinumab (Cosentyx, Novartis Pharma AG,
Basel, Switzerland), recently approved for the
treatment of adult patients with moderate to severe
plaque psoriasis, is a fully human IgG1kmonoclonal
antibody that selectively targets IL-17A.14 IL-17A isa key pathogenic cytokine in
psoriasis and acts directly on
keratinocytes to stimulate the
secretion of proinflammatory
mediators; the action of IL-23
on keratinocytes is more
remote but ultimately de-
pends on inducing IL-
17A.15,16 The clinical benefit
of TNF-a inhibition has been
linked to the suppression of
the IL-23/IL-17 axis.16,17 The
importance of IL-17A in
psoriasis pathogenesis has
been validated by the clinical
efficacy of secukinumab inpivotal 52-week phase III trials; secukinumab was
shown to be superior to placebo and to etanercept in
achieving a strong and sustained response with a
favorable safety profile.18-22 PASI 90 responses were
obtained by 70% to 72% of subjects treated with
secukinumab 300 mg at week 16 and sustained in the
majority of subjects at week 52.18 The magnitude of
improvement after 16 weeks of treatment with
secukinumab18 is higher than that reported in
phase III studies for etanercept,1,2 infliximab,3,4
adalimumab,5,6 and ustekinumab.7,8
Comparative efficacy among therapies is best
evaluated in rigorous head-to-head randomized
trials. CLEAR, the second head-to-head trial of
secukinumab, directly compared the efficacy and
safety of secukinumab with ustekinumab in subjects
with moderate to severe plaque psoriasis.
Ustekinumab is a human monoclonal antibody
directed against cytokines IL-12 and IL-23, the
latter of which, by activating T-helper 17 cells,
functions upstream of IL-17A in driving psoriasis
pathogenesis.15,16 Like secukinumab, ustekinumab
has shown superiority to etanercept in achieving
PASI 75 responses in a phase III study.23 The CLEAR
study, presented here, was designed with the
primary objective of demonstrating superiority of
secukinumab to ustekinumab in achieving PASI 90
response, a high-threshold clinical response that to
our knowledge has not been used as the primary end
Abbreviations used:
AE: adverse event
DLQI: Dermatology Life Quality Index
HRQoL: health-related quality of life
IGA: investigator global assessment
IGA mod 2011: investigator global assessment
2011 modified version
IL: interleukin
MedDRA: Medical Dictionary for Regulatory
Activities
PASI: Psoriasis Area and Severity Index
PASI 75: 75% or more improvement from
baseline Psoriasis Area and
Severity Index score
PASI 90: 90% or more improvement from
baseline Psoriasis Area and
Severity Index score
PASI 100: 100% improvement from baseline
Psoriasis Area and Severity Index
score
SAE: serious adverse event
TNF: tumor necrosis factor
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an ongoing 52-week study; week-16 primary end
point results are reported here.METHODS
Study population
Subjects (age $18 years) with moderate to severe
plaque psoriasis (as defined previously18) were
eligible. Subjects had a diagnosis of psoriasis at
least 6 months before randomization and had been
inadequately controlled by topical treatments,
phototherapy, and/or previous systemic therapy.
Key exclusion criteria included previous exposure
to any biologics directly targeting IL-17A/IL-17
receptor A or IL-12/IL-23.Study design
This 52-week, randomized, double-blind, active
comparator, parallel-group, superiority phase IIIb
study was conducted in accordance with ethical
principles of the Declaration of Helsinki at 134 sites
worldwide. US sites maintained compliance with
Health Insurance Portability and Accountability Act
regulations. The study was initiated in February 2014
(first subject, first visit), and last subject, last visit for
the week-16 primary efficacy analysis occurred in
October 2014.
Eligible subjects were randomized 1:1 via an
interactive response technology system to
subcutaneous injection of secukinumab 300 mg or
ustekinumab (dosing per label24: 45 mg for subjects
#100 kg at baseline; 90 mg for subjects[100 kg at
baseline). Randomization was stratified by body
weight (#100 kg and[100 kg). Secukinumab wasadministered at baseline and weeks 1, 2, and 3, then
every 4 weeks fromweek 4 to week 48; ustekinumab
at baseline and week 4, then every 12 weeks from
week 16 to week 40. To maintain blinding, placebo
injections matching the secukinumab regimen
were given to subjects in the ustekinumab group
(Fig 1).
The analyses presented herewere performed after
all subjects completed the primary end point visit
(week 16 [predose]). Full analysis of all data collected
up to week 52 will be performed after all subjects
have completed the week-52 visit. The designated
sponsor team performing the 16-week analysis was
unblinded after the 16-week database lock, whereas
the sponsor team in charge of data review, and
investigators, site personnel who evaluated subjects,
and subjects, remain blinded to individual treatment
allocation (blinding in place until after final database
lock at week 52).
Study objectives
The primary objective was to demonstrate
superiority of secukinumab versus ustekinumab
with respect to PASI 90 response at week 16.
Secondary objectives were to demonstrate
superiority of secukinumab versus ustekinumab
in achieving PASI 75 response at week 4 and PASI
90 response at week 52 (week-52 data will
be analyzed and reported at a later date). The
efficacy of secukinumab versus ustekinumab,
with respect to PASI 75/90/100 and investigator
global assessment (IGA) 2011 modified version
(IGAmod 2011) 0/1 (defined as IGA score of 0 [clear]
or 1 [almost clear] and improvement of $2 points vs
baseline25) responses over time, was also evaluated.
Subjects self-assessed symptoms of pain,
itching, or scaling on an 11-point numeric rating
scale (range, 0-10 points, higher scores indicate
worse symptoms), and reported on HRQoL using
the Dermatology Life Quality Index (DLQI). DLQI
has been validated for dermatologic conditions
(range, 0-30 points, higher scores indicate
greater impact on HRQoL).26 Safety and tolerability
were evaluatedby adverse event (AE), laboratory and
vital sign assessments, and physical examinations.
AEs were coded using the Medical Dictionary for
Regulatory Activities (MedDRA) terminology. The
study protocol and its amendments were reviewed
by the independent ethics committee or institutional
review board for each participating center.
Statistical analyses
Efficacy variables were assessed in the full
analysis set according to the treatment assigned at
randomization. A sequentially rejective testing
Fig 1. Study design. aTo maintain blinding, placebo injections matching the secukinumab
regimen were given to subjects in the ustekinumab group.
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hypotheses for primary and secondary efficacy
variables. Between-treatment comparisons of
clinical responses were made using a logistic
regression model with treatment group, randomized
strata, and baseline PASI score as explanatory
variables. Missing values with respect to response
variables based on PASI and IGA mod 2011 scores
were imputed as nonresponse (nonresponder
imputation). Missing values for these response
variables were also imputed using a multiple
imputation method. Fisher exact test was used to
compare DLQI 0/1 responses between treatments;
analysis of covariance was used for absolute change
from baseline in subjects’ assessment of pain, itching,
and scaling. For patient-reported outcomes, last
observation carried forward was used to manage
missing data.
A sample size of 320 subjects per group was
calculated for greater than 99% power to show PASI
90 response of 71% at week 16 in the secukinumab
group, assuming PASI 90 response of 51% at week 16
in the ustekinumab group,7,8 based on a 2-group x2
test of equal proportions.
RESULTS
Study population
Baseline demographic and disease characteristics
were similar between treatment arms, although there
was a slight numeric imbalance in subjects with
psoriatic arthritis (20.5% and 15.9% in thesecukinumab and ustekinumab groups, respec-
tively) (Table I). A total of 676 subjects were
randomized. Among these, 675 subjects were
included in the full analysis set for primary efficacy
analyses (1 subject was excluded [informed consent
was obtained the day after study-related procedure]);
671 subjects received at least 1 dose of study
treatment and were included in the safety analysis
(subject disposition in Fig 2).
Efficacy
Both the primary and secondary objectives
evaluated within 16 weeks in the testing procedure
were met (Table II). Secukinumab was superior to
ustekinumab with respect to the primary end
point of the study, with 79.0% of subjects in the
secukinumab group and 57.6% of subjects in
the ustekinumab group achieving a PASI 90
response at week 16 (P\ .0001). The proportion of
subjects achieving a PASI 100 response (clear
skin) at week 16 was significantly greater with
secukinumab (44.3%) compared with ustekinumab
(28.4%) (P\ .0001). Significantly higher efficacy of
secukinumab over ustekinumab was also observed
for PASI 75 and IGAmod 2011 0/1 responses at week
16 (Table II).
Secukinumab was superior to ustekinumab with
respect to efficacy in the initial treatment period,
with the proportion of subjects achieving the
secondary end point of a PASI 75 response at week
4: 50.0% in the secukinumab versus 20.6% in the
Table I. Baseline demographic and clinical
characteristics
Characteristic
Secukinumab
300 mg
(n = 337)
Ustekinumab
(n = 339)
Age, y 45.2 6 13.96 44.6 6 13.67
Male gender 229 (68.0) 252 (74.3)
Race
Caucasian 299 (88.7) 288 (85.0)
Other 38 (11.3) 51 (15.0)
Weight, kg 87.4 6 19.95 87.2 6 22.11
BMI, kg/m2 29.1 6 5.87 29.0 6 6.69
Time since psoriasis
diagnosis, y
19.6 6 12.90 16.1 6 11.24
PASI score 21.7 6 8.50 21.5 6 8.07
Body surface area
involved, %
32.6 6 17.78 32.0 6 16.80
IGA mod 2011 score
4 (Severe disease)* 130 (38.6) 125 (36.9)
Psoriatic arthritis reported 69 (20.5) 54 (15.9)
Previous systemic psoriasis
treatment
Any 225 (66.8) 231 (68.1)
Conventional agenty 218 (64.7) 223 (65.8)
Biologic agent 48 (14.2) 44 (13.0)
Failed biologic agent 36 (10.7) 34 (10.0)
PASI scores range from 0 (no disease) to 72 (maximal disease).
IGA mod 2011 scores range from 0 (clear skin) to 4 (severe
disease).
Data are given as n (%) or mean 6 SD.
BMI, Body mass index; IGA mod 2011, investigator global
assessment 2011 modified version; PASI, Psoriasis Area and
Severity Index.
*All other subjects had a score of 3 (moderate disease), with the
exception of 2 subjects who were recorded at baseline as having a
score of 2 (mild disease), which was corrected to a score of 3 after
the wk-16 database lock.
yIncluded methotrexate, cyclosporine, corticosteroids, and fumaric
acid esters.
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subjects achieving PASI 90, PASI 100, or IGA
mod 2011 0/1 responses at week 4 were also
significantly greater with secukinumab compared
with ustekinumab (Table II).
Overall, secukinumab achieved consistently
higher PASI 75/90/100 and IGA mod 2011 0/1
responses versus ustekinumab at each assessed
time point throughout 16 weeks of treatment
(Fig 3, A to D). Analyses of clinical responses using
themultiple imputationmethod (Table III) produced
numerically comparable results as those from the
primary, nonresponder imputation method.
Subject-reported outcomes
Subjects in the secukinumab group reported
greater improvement in pain, itching, and scaling
compared with the ustekinumab group (Table II).The percentage of subjects achieving a DLQI score of
0/1, indicating no impairment of HRQoL because of
skin problems, was significantly higher with
secukinumab than with ustekinumab at each
assessed time point through 16 weeks (week 16:
71.9% vs 57.4%, respectively; P\.0001) (Fig 3, E, and
Table II).
Safety
Both groups had similar duration of exposure
to study treatment. The proportion of subjects
experiencing at least 1 AE was 64.2% in the
secukinumab group and 58.3% in the ustekinumab
group. AEs in the system organ class of ‘‘Infections
and Infestations’’ were reported most often (29.3%
for secukinumab and 25.3% for ustekinumab);
however, most infectious AEs were nonserious, of
mild to moderate severity, easily manageable, and
did not lead to study drug discontinuation. The most
common AEs by MedDRA preferred term were
headache and mild to moderate nasopharyngitis in
both groups (Table IV).
No deaths occurred during the 16-week treatment
period. The incidence of serious AEs (SAEs) was low:
3.0% of subjects in each group. To maintain blinding
until after the final database lock at week 52, the
distributions of rare AEs across study treatments are
not presented in this report. A total of 20 subjects
experienced SAEs up to the 16-week database lock,
including 3 cases of infections (appendicitis,
diverticulitis, scrotal abscess), 2 cardiac events
(unstable angina, myocardial infarction), 1 case of
embolic stroke, 1 malignancy (lung adenocarci-
noma), 1 injection-related reaction with nausea/
vomiting, and 2 hepatic events (toxic hepatitis, acute
hepatitis). Both cases of hepatic SAEs were
confounded by concomitant isoniazid therapy and
improved/resolved after interruption of study
treatment and isoniazid. No cluster of SAEs was
observed and all SAEs were single events.
Among AEs of special interest, 12 cases of
nonserious, localized mucosal or cutaneous
Candida infections and 10 cases of oral herpes
infections were reported; all were mild or moderate
and none led to treatment discontinuation. There
were no AE reports of neutropenia, inflammatory
bowel disease, or tuberculosis.
DISCUSSION
Results of this study demonstrate that secukinu-
mab was superior to ustekinumab at week 16 in
clearing the skin of subjects with moderate to
severe plaque psoriasis and achieving a better
HRQoL improvement with a comparable safety pro-
file. Comparative effectiveness research, as done
Fig 2. Subject disposition. *Four subjects did not receive study treatment (2 withdrew consent;
1 because of technical problem; and 1 because of physician decision) and discontinued the
study at randomization; 1 subject was excluded from all analyses because the informed consent
form was obtained the day after study-related procedure. yIn all, 25 subjects discontinued
study treatment because of adverse event (7); lost to follow-up (3); protocol deviation
(5); subject/guardian decision (7); physician decision (1); noncompliance with study treatment
(1); and technical problem (1).
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However, evidence on comparative efficacy among
biologics in psoriasis is poor because of the limited
number of head-to-head trials. The CLEAR
study reported here included the IL-12/IL-23
inhibitor ustekinumab, an agent with a different
mechanism of action and higher efficacy than
etanercept,23 as the active biologic comparator with
secukinumab.
The CLEAR study shows that secukinumab was
superior to ustekinumab in achieving PASI 90
(primary end point) response at week 16; PASI 100
response was also statistically significantly greater in
the secukinumab group. Clinical responses with
secukinumab occurred earlier and were greater
than thosewith ustekinumab at each visit throughout
the 16-week treatment period. Consistent with its
higher clinical efficacy, secukinumab also achieved
significantly greater improvement in subject-
reported symptoms and with HRQoL (DLQI
0/1 response), compared with ustekinumab.
Secukinumab is currently the only biologic for which
superiority versus both anti-IL-12/IL-23 and an
antieTNF treatment has been demonstrated in pla-
que psoriasis. These results provide dermatologists
important head-to-head comparison information forconsideration when choosing an appropriate
therapy for patients with plaque psoriasis.
The threshold for treatment success in psoriasis
has been defined as a PASI 90 response. This
goal, however, was considered a ‘‘very stringent
requirement and a target not always possible to
obtain in clinical practice.’’9 Importantly, the current
findings with secukinumab show that a PASI 90
response was achieved in 79% of subjects and PASI
100 response in 44.3% of subjects after 16 weeks of
treatment. Thus, with secukinumab, these data show
that a PASI 90 response is now an achievable goal in a
majority of subjects.
No new or unexpected safety signals were
identified for secukinumab during the 16-week
treatment period. Secukinumab exhibited a safety
profile similar to that of ustekinumab and consistent
with that seen in secukinumab pivotal phase III
trials.18-20 The duration of the current primary
analysis (16 weeks) may not be long enough to
detect all rare AEs or AEs with long latency. In
addition, details of rare AEs were not reported in this
article according to the treatment arms in the current
analysis to maintain blinding. In previously
published studies, comprehensive and long-term
safety data for both secukinumab and ustekinumab
Table II. Efficacy end points
Secukinumab 300 mg Ustekinumab P value
PASI and IGA mod 2011 0/1 responses based
on nonresponder imputation method
PASI 100 response, no./N (%)
Wk 16 148/334 (44.3) 95/335 (28.4) \.0001
Wk 12 130/334 (38.9) 86/335 (25.7) .0003
Wk 4 14/334 (4.2) 3/335 (0.9) .0139
PASI 90 response, no./N (%)
Wk 16 (primary end point) 264/334 (79.0) 193/335 (57.6) \.0001
Wk 12 243/334 (72.8) 179/335 (53.4) \.0001
Wk 4 70/334 (21.0) 18/335 (5.4) \.0001
PASI 75 response, no./N (%)
Wk 16 311/334 (93.1) 277/335 (82.7) .0001
Wk 12 304/334 (91.0) 265/335 (79.1) \.0001
Wk 4 (secondary end point) 167/334 (50.0) 69/335 (20.6) \.0001
IGA mod 2011 0/1,* no./N (%)
Wk 16 277/334 (82.9) 226/335 (67.5) \.0001
Wk 12 270/334 (80.8) 218/335 (65.1) \.0001
Wk 4 126/334 (37.7) 41/335 (12.2) \.0001
Subject-reported outcomes
DLQI 0/1, no./N (%)
Wk 16 238/331 (71.9) 191/333 (57.4) \.0001
Wk 12 219/331 (66.2) 188/333 (56.5) .0109
Wk 4 111/325 (34.2) 70/331 (21.1) .0002
Subject-reported symptoms
Pain, mean score .0414
Baseline 4.1 3.8
Wk 16 0.8 1.0
Absolute change 3.3 2.8
Itching, mean score .0053
Baseline 6.3 6.2
Wk 16 1.2 1.6
Absolute change 5.0 4.6
Scaling, mean score .0001
Baseline 6.5 6.5
Wk 16 0.8 1.3
Absolute change 5.7 5.2
DLQI, Dermatology Life Quality Index; IGA mod 2011, investigator global assessment 2011 modified version; N, the number of evaluable
subjects; no., the number of subjects with a response; PASI, Psoriasis Area and Severity Index; PASI 75, 75% or more improvement from
baseline Psoriasis Area and Severity Index score; PASI 90, 90% or more improvement from baseline Psoriasis Area and Severity Index score;
PASI 100, 100% improvement from baseline Psoriasis Area and Severity Index score.
*IGA mod 2011 score of 0 (clear) or 1 (almost clear) and an improvement of $2 points from baseline.
J AM ACAD DERMATOL
SEPTEMBER 2015
406 Thac¸i et alhave been reported.18,28 The CLEAR study is ongoing
and results over the entire 52 weeks will be reported
at a later date.
The study does not have a placebo arm,
which might explain the slightly higher
response rates observed with secukinumab
and ustekinumab when compared with the
corresponding rates reported in previous placebo-
controlled studies.7,8,18-20 Cross-study comparisons,
however, must be viewed with caution. In addition,
both biologic treatments have previously
shown superior efficacy compared with placeboin phase III trials, making the inclusion of a
placebo arm of questionable ethical and scientific
value.
In conclusion, the head-to-head CLEAR study
demonstrates that secukinumab is superior to
ustekinumab in clearing skin of subjects with
moderate to severe plaque psoriasis with similar
safety. Greater clinical efficacy with secukinumab is
accompanied by significantly greater improvement
in HRQoL, compared with ustekinumab. IL-17A is a
key cytokine in the pathophysiology of psoriasis,
and selectively inhibiting IL-17A with secukinumab
Fig 3. Efficacy over time to week 16. Improvement from baseline Psoriasis Area and Severity
Index (PASI) score of 90% or more (PASI 90) (A), 100% (PASI 100) (B), or 75% or more
(PASI 75) (C). D, Investigator global assessment 2011 modified version (IGA mod 2011) 0/1
response. E, Dermatology Life Quality Index (DLQI ) 0/1 response. *P # .0001, yP \ .001,
zP\ .05. Missing values for PASI score response variables and IGA mod 2011 0/1 response
were imputed as nonresponses (nonresponder imputation). Only subjects who could be
evaluated for a response were included (subjects who had missed all postbaseline values were
excluded for that response variable). Missing values for DLQI were handled using last
observation carried forward.
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and antieTNF therapies in clinical trials. Results
from the CLEAR study add to the evidence from the
pivotal phase III program supporting that secuki-
numab can better deliver clear or almost clear skin
and improved HRQoL when compared with other
existing therapies, making it the new reference
standard treatment for patients with moderate to
severe plaque psoriasis.The authors thank the patients and investigators
who participated in the study. We would also like
to thank the following Novartis employees: Mirjam
Kuipers, Izabella Messina (clinical scientists); Achim
Guettner (statistician); Valda Murphy (project manager);
Tanvi Sharma (data manager); Yi Yang (programmer);
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Table III. Psoriasis Area and Severity Index and investigator global assessment 2011 modified version 0/1
responses based on the multiple imputation method
Secukinumab 300 mg Ustekinumab P value
PASI 100 response, no./N (%)
Wk 16 150/334 (45.0) 98/335 (29.3) \.0001
Wk 12 131/334 (39.3) 87/335 (26.0) .0003
Wk 4 14/334 (4.2) 3/335 (0.9) .0174
PASI 90 response, no./N (%)
Wk 16 (primary end point) 268/334 (80.1) 199/335 (59.5) \.0001
Wk 12 246/334 (73.5) 182/335 (54.4) \.0001
Wk 4 70/334 (21.0) 18/335 (5.5) \.0001
PASI 75 response, no./N (%)
Wk 16 315/334 (94.3) 283/335 (84.5) .0001
Wk 12 307/334 (91.8) 272/335 (81.1) .0001
Wk 4 (secondary end point) 168/334 (50.3) 70/335 (20.9) \.0001
IGA mod 2011 0/1,* no./N (%)
Wk 16 281/334 (84.1) 233/335 (69.5) \.0001
Wk 12 273/334 (81.7) 224/335 (66.9) \.0001
Wk 4 127/334 (38.0) 42/335 (12.4) \.0001
IGA mod 2011, Investigator global assessment 2011 modified version (IGA mod 2011); N, the number of evaluable subjects; no., the number
of subjects with a response; PASI 75, 75% or more improvement from baseline Psoriasis Area and Severity Index score; PASI 90, 90% or more
improvement from baseline Psoriasis Area and Severity Index score; PASI 100, 100% improvement from baseline Psoriasis Area and Severity
Index score.
*IGA mod 2011 score of 0 (clear) or 1 (almost clear) and an improvement of $2 points from baseline.
Table IV. Adverse events during the 16-wk
treatment period of CLEAR study
Secukinumab
300 mg (n = 335)
Ustekinumab
(n = 336)
Exposure to study
treatment, d
111.1 6 10.21 110.3 6 14.76
Subjects with any AE 215 (64.2) 196 (58.3)
Death 0 0
Nonfatal serious AE 10 (3.0) 10 (3.0)
Discontinuations
because of AE
3 (0.9) 4 (1.2)
Infections and infestations 98 (29.3) 85 (25.3)
Most common AE*
Headache 26 (7.8) 27 (8.0)
Nasopharyngitis 23 (6.9) 34 (10.1)
Diarrhea 14 (4.2) 12 (3.6)
Fatigue 14 (4.2) 9 (2.7)
Arthralgia 13 (3.9) 14 (4.2)
Data are given as n (%) or mean 6 SD.
AE, Adverse events.
*Expressed by preferred term and occurring at an incidence of
$4% in either treatment arm during the 16-wk treatment period.
AEs are listed in decreasing order of frequency in the secukinumab
arm.
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